The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database

BackgroundTeduglutide, the first glucagon-like peptide 2 analogue, has been demonstrated to facilitate the absorption of gut nutrient and lessen the need for parenteral assistance in patients with Short Bowel Syndrome (SBS). However, its adverse drug events (AEs) are primarily documented in clinical...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Xiaogan Wang, Hao Chen, Shuangshuang Han, Lingbo Li, Hongjin Chen, Bolin Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-09-01
Subjects:	teduglutide glucagon-like peptide 2 adverse drug events disproportionality analysis pharmacovigilance
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1404658/full